Paper32406985
Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient.
Allam SR and 6 others. Transpl Infect Dis, 2020. Cited by 17 papers, by iCite.
Cite this record
ConductScience Library. Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient. Papers, record 32406985. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32406985
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal, Humanized | Major topic |
| Betacoronavirus | Major topic |
| Coronavirus Infections | Major topic |
| Pneumonia, Viral | Major topic |
| Receptors, Interleukin-6 | Major topic |
| Aged | |
| Biomarkers | |
| COVID-19 | |
| Female | |
| Humans | |
| Inflammation | |
| Kidney Transplantation | |
| Pandemics | |
| SARS-CoV-2 | |
| Transplant Recipients |
Source PubMed
Cited by15
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 35483235 | Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials. | Int Immunopharmacol | 2022 | https://conductscience.org/library/papers/35483235 | PubMed |
| 35400860 | Coronavirus-19 infection in kidney transplant recipients: A comprehensive review. | Indian J Urol | 2022 | https://conductscience.org/library/papers/35400860 | PubMed |
| 34987916 | Early Fall in C-Reactive Protein (CRP) Level Predicts Response to Tocilizumab in Rapidly Progressing COVID-19: Experience in a Single-Arm Pakistani Center. | Cureus | 2021 | https://conductscience.org/library/papers/34987916 | PubMed |
| 34551880 | SARS-CoV-2 in Solid Organ Transplant Recipients: A Structured Review of 2020. | Transplant Proc | 2021 | https://conductscience.org/library/papers/34551880 | PubMed |
| 33946462 | The Management of Immunosuppression in Kidney Transplant Recipients with COVID-19 Disease: An Update and Systematic Review of the Literature. | Medicina (Kaunas) | 2021 | https://conductscience.org/library/papers/33946462 | PubMed |
| 33641202 | Effect of immunosuppression maintenance in solid organ transplant recipients with COVID-19: Systematic review and meta-analysis. | Transpl Infect Dis | 2021 | https://conductscience.org/library/papers/33641202 | PubMed |
| 33387393 | COVID-19 in SOT versus non-SOT. | Am J Transplant | 2021 | https://conductscience.org/library/papers/33387393 | PubMed |
| 33246166 | COVID-19 in solid organ transplant recipients: A systematic review and meta-analysis of current literature. | Transplant Rev (Orlando) | 2021 | https://conductscience.org/library/papers/33246166 | PubMed |
| 33240518 | Management of Canadian Pediatric Patients With Glomerular Diseases During the COVID-19 Pandemic: Recommendations From the Canadian Association of Pediatric Nephrologists COVID-19 Rapid Response Team. | Can J Kidney Health Dis | 2020 | https://conductscience.org/library/papers/33240518 | PubMed |
| 33240516 | Management of Pediatric Kidney Transplant Patients During the COVID-19 Pandemic: Guidance From the Canadian Society of Transplantation Pediatric Group. | Can J Kidney Health Dis | 2020 | https://conductscience.org/library/papers/33240516 | PubMed |
| 33110739 | Immunomodulatory Therapies for COVID-19 in Solid Organ Transplant Recipients. | Curr Transplant Rep | 2020 | https://conductscience.org/library/papers/33110739 | PubMed |
| 32947798 | A Systematic Review of COVID-19 Infection in Kidney Transplant Recipients: A Universal Effort to Preserve Patients' Lives and Allografts. | J Clin Med | 2020 | https://conductscience.org/library/papers/32947798 | PubMed |
| 32884871 | COVID-19 and Hyperinflammatory Syndrome in Children: Kawasaki Disease with Macrophage Activation Syndrome in Disguise? | Cureus | 2020 | https://conductscience.org/library/papers/32884871 | PubMed |
| 32650019 | Interleukin 6 levels after tocilizumab administration in transplant recipients with COVID-19. | Kidney Int | 2020 | https://conductscience.org/library/papers/32650019 | PubMed |
| 32568186 | The compelling arguments for the need of microvascular investigation in COVID-19 critical patients. | Clin Hemorheol Microcirc | 2020 | https://conductscience.org/library/papers/32568186 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32406985
GET https://conductscience.org/api/papers/v1/32406985/authors